Professional Documents
Culture Documents
RNTCP at A Glance
RNTCP at A Glance
RNTCP at a Glance
5
DIAGNOSTIC ALGORITHM FOR PULMONARY TB
3 Sputum smears
2 or 3 Positives 3 Negatives
Cough Persists
6 RNTCP at a Glance
STAINING METHOD
Key steps in the preparation and staining of smears
Step 1
Break a broomstick Pick up the large, yellow purulent Spread evenly onto 2/3
into two portion of sputum Spread evenly of central portion of the
onto 2/3 of central portion of the numbered slide
numbered slide
Step 8 Step 9
Decolourize with 25% sulphuric acid and Rinse away excess Drain off the
let it stand for 2–4 minutes (repeat, letting stain with tap water water
stand for 1–3 minutes, if necessary)
Step 10
Counterstain with 0.1% Gently rinse the slides with Examine the slides under
methylene blue and let tap water, drain the water the microscope examine
stand for 30 seconds off, and allow the slide to dry at least 100 fields.
RNTCP at a Glance 7
Ziehl - Neelsen Staining Method
1. Select a new unscratched slide and label the slide with the Laboratory Serial
Number with a diamond marking pencil.
2. Make a smear from yellow purulent portion of the sputum using a broom stick. A
good smear is spread evenly, 2 cms x 3 cms in size and is neither too thick nor
too thin. The optimum thickness of the smear can be assessed by placing the
smear on a printed matter. The print should be readable through the smear. Smear
preparation should be done near a flame. This is required, as six inches around the
flame is considered as a sterile zone which coagulates the aerosol raised during
smear preparation.
3. Allow the slide to air dry for 15–30 minutes.
4. Fix the slide by passing it over a flame 3–5 times for 3–4 seconds each time.
5. Pour 1% filtered carbol fuchsin to cover the entire slide.
6. Gently heat the slide with carbol fuchsin on it, until vapours rise. Do not boil.
7. Leave carbol fuchsin on the slide for 5 minutes.
8. Gently rinse the slide with tap water until all free carbol fuchsin stain is washed
away. At this point, the smear on the slide looks red in colour.
9. Pour 25% sulphuric acid onto the slide.
10. Let the slide stand for 2–4 minutes.
11. Rinse gently with tap water. Tilt the slide to drain off the water.
12. A properly decolourised slide will appear light pink in color .If the slide is still red,
reapply sulphuric acid for 1–3 minutes and rinse gently with tap water. Wipe the
back of the slide clean with a swab dipped in sulphuric acid,
13. Pour 0.1% methylene blue onto the slide.
14. Leave methylene blue on the slide for 30 seconds.
15. Rinse gently with tap water.
16. Allow the slide to dry.
17. Examine the slide under the microscope using x 40 lens to select the suitable area
and then examine under x100 lens using a drop of immersion oil.
18. Record the results in the Laboratory Form and the Laboratory Register.
If the slide has: Result Grading No. of fields to be examined
More than 10 AFB per oil immersion field Pos 3+ 20
1-10 AFB per oil immersion field Pos 2+ 50
10-99 AFB per 100 oil immersion fields Pos 1+ 100
1-9 AFB per 100 oil immersion fields Pos Scanty-B* 100
No AFB in 100 oil immersion fields Neg 100
19. Invert the slides on tissue paper till the immersion oil is completely absorbed.
Do not use xylene for cleaning the slides, as it may give false results at repeat
examination after storage.
20. Store all positive and negative slides serially in the same slide-box until instructed
by the supervisor.
21. Disinfect all contaminated material before discarding.
8 RNTCP at a Glance
TREATMENT
NO YES
Does the patient have TB? Has the patient been treated
for TB for one month or more
YES
previously
NO
NO YES
Is the patient
seriously ill?**
NO YES
No Anti-TB
treatment
* Patients with extra-pulmonary TB should receive Category III treatment unless they are seriously ill, in
which case they should receive Category I treatment.
** Examples of seriously ill patients are those suffering from meningitis, disseminated TB, tuberculous
pericarditis, peritonitis, bilateral or extensive pleurisy, spinal TB with neurological complications, smear-
negative pulmonary TB with extensive parenchymal involvement, intestinal, genito-urinary TB and
co-infection with HIV. All forms of pediatric smear negative TB except primary complex and pediatric
extrapulmonary TB except lymph node TB and unilateral pleural effusion.
RNTCP at a Glance 9
TREATMENT CATEGORIES AND SPUTUM EXAMINATION SCHEDULE
TREATMENT REGIMEN SPUTUM EXAMINATIONS FOR PULMONARY TB
Category of Type of patient Regimen* Pre-treatment Test at If result Then
Treat ment sputum month is
(end IP)
10 RNTCP at a Glance
Seriously ill** extra-pulmonary –
the end of treatment (6 months)
Continue Intensive phase for one more
– 2 month, test sputum again at end of extended
+ IP (3 months), and then at 2 months in CP
(5 months) and at the end of treatment (7
months)†
Sputum smear-positive Relapse 2H3R3Z3E3S3 +
Start continuation phase, test sputum again at
Sputum smear-positive Failure 1H3R3Z3E3 +
5H3R3E3 – 2 months in CP (5 months) and at the end of
Sputum smear-positive Treatment after treatment (8 months)
default 3
Category II Others*** + Continue Intensive phase for one more
month, test sputum again at end of extended
+ IP (4 months), and then at 2 months in CP
(6 months) and at the end of treatment (9
months)
New sputum smear-negative, 2H3R3Z3 +
Start continuation phase, test sputum again at
not seriously ill 4H3R3 2 –
the end of treatment (6 months)
Category III New extra-pulmonary, not seriously ill –
Re-register the patient and begin Category II
+
treatment†
* The number before the letters refers to the number of months of treatment. The subscript after the letters refers to the number of doses per week. The dosage strengths are as
follows: H: Isoniazid (600 mg), R: Rifampicin (450 mg), Z: Pyrazinamide (1500 mg), E: Ethambutol (1200 mg), S: Streptomycin (750 mg). Patients who weigh 60 kg or more
receive additional rifampicin 150 mg. Patients who are more than 50 years old receive streptomycin 500 mg. Patients who weigh less than 30 kg, receive drugs as per body
weight. Patients in Categories I and II who have a positive sputum smear at the end of the initial intensive phase receive an additional month of intensive phase treatment.
** Seriously ill also includes, any patient, pulmonary or extra-pulmonary who is HIV positive and declares his sero-status to the categorizing/ treating medical officer. For the purpose
of categorization, HIV testing should not be done
*** In rare and exceptional cases, patients who are sputum smear-negative or who have extra-pulmonary disease can have Relapse or Failure. This diagnosis in all such cases should
always be made by an MO and should be supported by culture or histological evidence of current, active TB. In these cases, the patient should be categorized as ‘Others’ and
given Category II treatment.
† Any patient treated with Category I who has a positive smear at 5 months or later should be considered a Failure and started on Category II treatment afresh. Any patient on
Category III who has a positive smear anytime during the treatment is also considered as Failure and started on Category II treatment.
MEDICATION
Medication Dose (thrice a week)*** Number of pills in
combipack
Isonazid 600mg 2
Rifampicin 450mg* 1
Pyrazinamide 1500mg 2
Ethambutol 1200mg 2
Streptomycin 0.75g** -
* Patients who weigh 60kg or more at the start of treatment are given an extra 150mg dose of rifampicin
** Patients over 50 years of age and those who weigh less than 30 kg are given 0.5g of streptomycin.
*** Adult patients who weigh less than 30kg receive drugs in patient-wise boxes from the weight band
suggested for pediatric patients
RNTCP at a Glance 11
MANAGEMENT OF PATIENTS WHO INTERRUPT TREATMENT
12 RNTCP at a Glance
MANAGEMENT OF PATIENTS WHO INTERRUPT TREATMENT
RNTCP at a Glance 13
MANAGEMENT OF PATIENTS WHO INTERRUPT TREATMENT
14 RNTCP at a Glance
TREATMENT OF CHILDREN
Diagnostic Algorithm for Pediatric Pulmonary TB
Pulmonary TB Suspect
Fever and/or cough 3 weeks
Loss of wt/ No wt. gain
History of contact with suspected or diagnosed case of active TB
Is expectoration present?
2 or 3 Positives 3 Negatives
Cough Persists
Repeat 3 Sputum
Examinations
1 Positive
Patient on treatment
Category II
No improvement =
Pediatric non-responder
16 RNTCP at a Glance
Dosages for children
Drugs Dosage (Thrice a week)
Isonoazid 10-15mg/kg
Rifampicin 10mg/kg
Pyrazinamide 35mg/kg
Streptomycin 15mg/kg
Ethambutol 30mg/kg
For asymptomatic children and those who are not found to be suffering
from TB, chemoprophylaxis with isoniazid (5 mg per kg body wt) should be
administered daily for a period of six months.
RNTCP at a Glance 17
SYMPTOM-BASED APPROACH TO EVALUATION OF POSSIBLE
SIDE EFFECTS OF ANTI-TB DRUGS USED IN RNTCP
Symptom Drug (abbreviation) Action to be taken
Gastrointestinal Any oral medication Reassure patient
upset Give drugs with less water
Give drugs over a longer period of
time (e.g. 20 minutes)
Do not give drugs on empty stomach
If the above fails, give antiemetic if
appropriate
Reassure patient
Isoniazid (H) (Other
Itching If severe, stop all drugs and refer
drugs also)
patient to MO
Burning in the Give pyridoxine 100 mg/day until
Isoniazid (H)
hands and feet symptoms subside
If severe, refer patient for
Joint pains Pyrazinamide (Z)
Evaluation
STOP ethambutol, refer patient for
Impaired vision Ethambutol (E)
evaluation
Ringing in the STOP streptomycin, refer patient for
Streptomycin (S)
ears evaluation
STOP streptomycin, refer patient for
Loss of hearing Streptomycin (S)
evaluation
Dizziness and STOP streptomycin, refer patient for
Streptomycin (S)
loss of balance evaluation
Isoniazid (H)
STOP all drugs, refer patient for
Jaundice Rifampicin (R)
evaluation
Pyrazinamide (Z)
18 RNTCP at a Glance
MANAGEMENT OF TB PATIENTS ON DOT IN SPECIAL SITUATIONS
Situation Management
Hospitalization • Only extremely ill patients need hospitalization during the
treatment
• Patients with significant haemoptysis, pneumothorax or large
accumulation of pleural fluid leading to breathlessness need to
be hospitalized
• Flow chart for hospitalized patients is given on next page
Tuberculous • Fatal if untreated
meningitis • Patient should be referred to the hospital
• Total duration of treatment is 8–9 months. The continuation
phase should be given for 6–7 months
• Steroids should be given initially and gradually reduced over
6–8 weeks
Treatment of TB • Streptomycin should not be given; other drugs used in RNTCP
during pregnancy are safe
and postnatal • Breast feeding should continue regardless of the mother’s TB
period status
• Advise the mother to cover her mouth, if she is smear-positive,
while breastfeeding the baby
• Chemoprophylaxis for the baby is advisable if mother is sputum
smear-positive
Treatment in • Rifampicin, isoniazid and pyrazinamide can be safely given
patients with renal • Streptomycin and ethambutol, if given, should be closely
failure monitored with reduced dosage
Treatment in • Rifampicin decreases the efficiency of oral contraceptives;
women taking oral increase the dosage of the oral contraceptive or switch to
contraceptive pills another method of contraception
TB and HIV • Anti-TB Treatment is same for HIV-infected people as it is for
HIV negative TB patients
• DOT assumes greater importance for HIV infected patients
• All new TB cases who are known to be HIV positive based
on voluntary sharing of results and/or history of anti-retroviral
therapy are considered to be seriously ill
• Patients with TB-HIV should complete their TB treatment prior
to beginning ART (if not already on ART). If patient is already
on ART, it should be modified to be rifampicin-friendly
MDR TB • MDR-TB is drug resistant TB caused due to bacilli resistant to
Isoniazid and Rifampicin, with or without resistance to other
anti TB drugs.
• Management of MDR –TB is very complex
• Prevention of MDR–TB rather than its treatment is the priority
under RNTCP
RNTCP at a Glance 19
HOSPITALIZATION OF TB PATIENTS
Some TB patients may need hospitalization during their illness. All indoor
patients are to be treated with RNTCP regimens. The treatment is given using
prolongation pouches which will be supplied by District TB Officer through
the STS of that TU. On discharge, patients may be given a maximum of three
doses (1 week drug supply) to cover the intervening period prior to their
continuation of treatment at their respective DOT Centre, which may/not be
in the same district, hence ensuring no interruption in treatment. All indoor
patients treated under RNTCP, should be registered under the local TU in
which the hospital is located.
20 RNTCP at a Glance
SUPERVISORY VISITS
RNTCP at a Glance 21
SUMMARY OF KEY INDICATORS AND POSSIBLE CORRECTIVE ACTIONS
Case Finding Indicators and possible responses to problems
Quarterly Report Indicator Possible Actions
Expected: New smear- Annualized Ensure that every TB suspect in all peripheral health facilities undergo sputum smear examination (in at
positive cases case registered number of least 2% of new adult outpatients).
detection of ≥ 70% new smear-positive Ensure that 3 sputum smear examinations are done for TB suspects.
cases is <50% Ensure that sputum smear microscopy is done correctly (5%–15% positivity is expected among patients
examined for diagnosis). Intensify review of slides read as smear-negative, particularly those of patients
placed on treatment.
Ensure that all smear-positives in the Laboratory Register are started on treatment and registered in the
TB Register.
Ensure that sputum smear microscopy is accessible to patients, and the laboratory technician is trained.
22 RNTCP at a Glance
Annualized Ensure that no active case-finding is being done in any area.
registered number of Ensure that sputum smear microscopy is accurate.
new smear-positive Ensure review of slides of smear-positive patients.
cases is >100% Ensure that only patients who reside in the area are started on treatment, and non-resident patients are
referred for treatment to health facilities in the areas that they reside in.
Expected: Re-treatment Re-treatment cases Ensure that accurate history taking is done at all levels. Patients must be asked carefully about any
smear-positive cases are <20% of all prior treatment taken for TB from any source. It should be explained to patients that only if they provide
are about 30% of all smear -positive cases accurate information can the most effective treatment be given.
smear-positive cases in Make sure that definitions are applied correctly. Any smear-positive patient treated in the past for more
initial years of RNTCP than one month and has defaulted for more than two months, should receive the re-treatment (Category
implementation II) regimen
Re-treatment cases Ensure that active case-finding is not being resorted to. With active case-finding, many ‘old’ TB cases are
are >40% of all reported.
smear-positive cases Ensure that history-taking is accurate and definitions are being correctly applied.
Ensure that new symptomatic patients undergo three sputum smear examinations for acid-fast bacilli
(AFB).
Expected: 50% of all new Among new Ensure that over-diagnosis of sputum smear-negative patients is not happening due to over reliance on
pulmonary cases will be pulmonary cases, radiography. No patient should begin treatment without the mandatory three sputum smear examinations.
smear-positive proportion of smear- Ensure that 3 sputum smears are examined for all TB suspects.
positive is <45% Ensure that repeat sputum smear examinations are done for patients who continue to have symptoms
after a course of antibiotics.
Ensure that sputum smear microscopy is done correctly. Review slides of smear negative patients placed
on treatment.
Expected: Not more than Proportion of smear- Ensure that only seriously ill patients are given Category I treatment. Non-seriously ill New smear-negative
20% of smear-negative and negative or extra- patients should receive Category III treatment.
extra-pulmonary patients pulmonary seriously Ensure that sputum microscopy is done correctly. Arrange review of slides of smear-negative patients
are considered seriously ill ill patients given placed on treatment.
and placed under Category Category I regimen is
I >25%
Sputum Conversion Indicators and possible responses to problems
Quarterly Report Indicator Possible Actions
Expected: Less than 85% of Ensure that Medical Officers, treatment supervisors, and all other staff involved in the
Conversion rate is >90% of New smear-positive programme at peripheral centres understand the importance of follow-up sputum examinations.
new smear-positive patients at 3 patients are documented Follow-up sputum examinations are the best measure of patient response to treatment.
months to become sputum smear- Conversion of sputum at the end of IP increases patient confidence and is critical to
negative at 3 months programme evaluation.
Visit all centres with low sputum conversion rate and resolve any problem with the help of the
staff.
Make sure default rates in the first two months are <5%, and the number of patients who die
or transferred out are minimized.
Ensure that accurate history-taking takes place at all levels. Patients must be asked carefully
about any prior treatment for TB from any source. It should be explained to patients that only
if they provide accurate information can effective treatment be given. If previously treated
patients are not placed on the re-treatment regimen, they may not respond well to treatment.
Make sure that definitions are applied correctly. Any smear-positive patient treated for more
than one month in the past and with a default of more than two months, should receive the
re-treatment (Category II) regimen.
Ensure that sputum microscopy is accurate. Ensure review of slides of patients who remained
smear positive at the end of the intensive phase.
Ensure that every dose of medication is observed during the intensive phase of treatment.
Observation sites should be convenient to the patient. The quality of DOTS should be checked
at the time of supervision, including checking of entries in the Treatment Cards with the drugs
available in patient-wise boxes.
RNTCP at a Glance 23
Result of Treatment Indicators and possible solution to problems
Quarterly Report Indicator Possible Actions
Expected: Cure rate Cure rate of Visit centres with low cure rates to discuss with patients and staff the reasons for low cure rate and
for new smear-positive new smear-positive possible solutions.
cases is ≥85% patients Ensure that accurate history-taking takes place at all levels. Patients must be asked carefully about any prior
is <80% treatment for tuberculosis taken from any source. It should be explained to patients that only if they provide
accurate information can the most effective treatment be given. If previously treated patients are not given
the re-treatment regimen, they may not respond well to treatment.
24 RNTCP at a Glance
Make sure that definitions are applied correctly. Any smear-positive patient treated for more than one month
in the past, with default of more than two months, should receive the re-treatment (Category II) regimen.
Ensure that every dose of medication is observed during the intensive phase of treatment, and at least one
dose per week in the continuation phase. Ensure return of empty blister packs during weekly collection of
drugs. Observation sites should be convenient for the patient.
Ensure that health workers are dispensing medication properly as per technical guidelines.
Ensure that follow-up sputum smear examinations are done according to guidelines.
Cure rate of new Check for the accuracy of the report. Make sure that Result of Treatments are correctly recorded and
smear- positive CAT I reported. All diagnosed smear-positive patients started on treatment should be registered.
patients is >95%
Expected: Not more Proportion of new Ensure that follow-up sputum examinations are done as per policy. Carefully track this at all treatment units.
than 3% of new smear- smear- positive Sensitize the Medical Officers and other health staff about the importance of follow-up sputum
positive patients are patients who are examinations.
given the classified as having
‘completed’ treatment Locate patients who have recently completed treatment and obtain sputum samples for examination.
is >5% Carefully review the patient data for accuracy and to ensure that treatment is being given under direct
observation as per policy.
Expected: Not more Proportion of new Ensure that every dose of medication is observed during the intensive phase of treatment, and at least one
than 4% of new smear- smear- dose per week in the continuation phase. Observation sites should be convenient to the patient.
positive patients die positive patients who Review information on patients who died to determine reasons.
during treatment
die during treatment is If patients are presenting for treatment when already moribund, consider ways and means to encourage
>5% more prompt referral and diagnosis so that patients can be treated earlier in the course of their TB illness.
In-spite of all the above, if the death rate is still more than 5%, consider evaluation of the prevalence of HIV
infection among TB patients, to be done strictly as per policy with safeguards of confidentiality.
Expected: Proportion of new Ensure that accurate history-taking is done at all levels. Patients must be asked carefully about prior
Failure: Not more than smear-positive patients treatment for tuberculosis from any source. It should be explained to patients that only if they provide
4% of new smear- who fail treatment is accurate information can the most effective treatment be given. If previously treated patients are not given
positive patients the re-treatment regimen, they may not respond well to treatment.
>5%
continue to be smear- Make sure that definitions are applied correctly. Any smear-positive patient treated for more than one month
positive at 5 months or in the past, with default of more than two months, should receive the re-treatment (Category II) regimen.
later from the start of Ensure that every dose of medication is observed during the intensive phase of treatment and at least one
treatment dose per week in the continuation phase. Ensure return of empty blister packs during weekly collection of
drugs in the continuation phase. Observation sites should be convenient to the patient.
Ensure that health workers are dispensing medication properly as per technical guidelines.
Ensure that drugs are of acceptable quality, stored in appropriate conditions and are used before the expiry
period.
In-spite of all the above, if the failure rate remains higher than 5%, consider evaluation of the level of primary
drug resistance in the community.
Expected Default rate of smear- Visit centres which have reported the highest default rates and interview staff and patients to determine the
Default rate is <5% positive Category I efforts made to retrieve patients, the reasons for default and possible solutions. Make sure that centres are
aware of their default rate so that they can take steps to reduce it.
patients is >8%
Ensure that patient history is carefully ascertained, including the address. A visit to patients’ home should
be made to verify address and landmarks near the house should be recorded in the Treatment Card. Services
should be convenient to the patient in terms of distance, time and staff attitudes.
During the visit to the house for verification of address, note the name and address of a person who can be
contacted in the event the patient defaults.
Ensure that directly observed treatment is given to patients in the intensive phase and at least one dose per
week is directly observed during the continuation phase.
Transfer out can be a way of disguising default. Patients should be categorized as ‘Transferred out’ only if
Expected: Proportion of patients they have been given a Transfer Form to be taken to the facility where they are transferred to.
Transferred out is <3% who are ‘Transferred Ensure the receipt of results of follow up sputum examinations and treatment
out’ is >5%
RNTCP at a Glance 25
New Indicators
Indicators Formula Comments
% new smear positive out of Nos. of NSP cases registered in the quarter / Total Nos. of new pulmonary (NSP+NSN) cases Expected value is 50%.
total new pulmonary cases registered in the same quarter X 100
% of new extra pulmonary Nos. of new extrapulmonary cases registered / Nos. of new cases registered (NSP+NSN+new Expected value is 10-
cases out of all new cases extra pulmonary) X 100 15%
% of retreatment cases out of Total Nos. of smear positive retreatment cases (Relapse, Failure, Treatment after default, Others)
all smear positive cases registered / Total Nos. of smear positive cases (new smear positive pulmonary cases + smear
positive retreatment cases) X 100
% of pediatric cases out of all Total Nos. of new pediatric cases registered (new smear positive pulmonary pediatric cases + new
26 RNTCP at a Glance
new cases smear negative pulmonary pediatric cases + new extra pulmonary pediatric cases) / Total Nos. of
new cases registered (NSP+NSN+ new extrapulmonary) X 100
% smear positive patients Nos. of sputum positive patients put on RNTCP DOTS during the quarter in the district / (Nos. Expected value > 95%
living in the district placed on of sputum positive patients diagnosed during the respective quarter – Nos. of sputum positive
DOTS patients referred for treatment outside the district) X 100
% of smear positive patients Nos. of sputum positive patients put on RNTCP Non-DOTS during the quarter in the district / (Nos. Expected value less than
placed on Non-DOTS treatment of sputum positive patients diagnosed during the respective quarter – Nos. of sputum positive 5%
regimen patients referred for treatment outside the district) X 100
% of initial defaulters Nos. of sputum positive patients diagnosed who are neither put on RNTCP DOTS or RNTCP
Non-DOTS in the district, or referred for treatment outside the district / (Nos. of sputum positive
patients diagnosed during the respective quarter – Nos. of sputum positive patients referred for
treatment outside the district) X 100
% of new smear positive cases Nos. of sputum positive patients diagnosed started on treatment with in 7 days of diagnosis / Total Data obtained from TB
started on RNTCP DOTS within Nos. of sputum positive patients diagnosed X 100 register
7 days of diagnosis
% of new smear positive cases Nos. of sputum positive patients diagnosed and started on treatment under RNTCP, who are Data obtained from TB
registered within one month of registered within 1 month of diagnosis / Total Nos. of sputum positive patients diagnosed X 100 register
diagnosis
% of interviewed new smear Nos. of interviewed NSP cases who received DOT as per guidelines (>21/24 doses)/ Total Nos. of Data obtained from
positive cases who received NSP cases interviewed X 100 Patients interviews during
DOT during Intensive Phase as supervisory field visits
per guidelines
% of cured NSP cases having Nos. of NSP cases registered during the quarter having an outcome cured, who had their end of Data obtained from TB
end of treatment follow-up treatment sputum examined within 7 days of last dose/ Total Nos. of NSP cases registered during register
sputum done within 7 days of the respective quarter with treatment outcome as cured X 100
last dose
NSP- New Smear Positive; NSN- New Smear Negative
RNTCP at a Glance 27
Due dates for reports from Tuberculosis Units to
DTC in the year 2006
Due On Quarterly Report on Period Covered
Case Finding 1 October – 31 December 2005
Programme Management 1 October – 31 December 2005
7 January 2006
Sputum Conversion 1 July – 30 September 2005
Results of Treatment 1 October – 31 December 2004
Case Finding 1 January – 31 March 2006
Programme Management 1 January – 31 March 2006
7 April 2006
Sputum Conversion 1 October – 31 December 2005
Results of Treatment 1 January – 31 March 2005
Case Finding 1 April – 30 June 2006
Programme Management 1 April – 30 June 2006
7 July 2006
Sputum Conversion 1 January – 31 March 2006
Results of Treatment 1 April – 30 June 2005
Case Finding 1 July – 30 September 2006
Programme Management 1 July – 30 September 2006
7 October 2006
Sputum Conversion 1 April – 30 June 2006
Results of Treatment 1 July – 30 September 2005
The District TB Officer is to retain one copy of records and send the quarterly reports to the state TB Officer.
All reports to reach Central TB Division by the 24th of the month. Reports to be sent to
quarterlyreports@tbcindia.org